Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.36 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785522 | 0.90 | OPRM1 (0.43) | EPHA2OPRM1OPRK1CXCR4 | |
| SCHEMBL10377176 | 0.89 | EPHA2 (0.49) | EPHA2OPRM1OPRK1CXCR4 | |
| SCHEMBL7786086 | 0.89 | OPRM1 (0.45) | EPHA2OPRM1OPRK1CXCR4F2 | |
| SCHEMBL10533153 | 0.87 | EPHA2 (0.49) | EPHA2OPRM1OPRK1CXCR4 | |
| SCHEMBL23034489 | 0.85 | F2 (0.40) | OPRM1OPRK1F2PRSS1F10 | |
| SCHEMBL8606332 | 0.85 | OPRM1 (0.44) | EPHA2OPRM1OPRK1CXCR4F2 | |
| SCHEMBL7780965 | 0.85 | NMUR2 (0.43) | EPHA2OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL31124690 | 0.82 | OPRM1 (0.43) | EPHA2OPRM1OPRK1CXCR4NMUR2 | |
| SCHEMBL31437194 | 0.81 | ACE (0.42) | EPHA2OPRM1OPRK1CXCR4 | |
| SCHEMBL9450491 | 0.81 | OPRM1 (0.46) | EPHA2OPRM1F2NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0723454-B1 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | GOLDSTEIN GIDEON (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0723454-A4 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | IMMUNOBIOLOGY RES INST INC (US) | 1998-07-29 | — | — | EP | claimed |
| US-5639729-A | NERVOUS SYSTEM DISORDERS | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1997-06-17 | — | — | US | claimed |
| EP-0723454-A1 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | Goldstein, Gideon (US) | 1996-07-31 | — | — | EP | claimed |
| WO-1995005841-A1 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1995-03-02 | — | — | WO | claimed |
| EP-0723454-B1 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | GOLDSTEIN GIDEON (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0723454-A4 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | IMMUNOBIOLOGY RES INST INC (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5639729-A | NERVOUS SYSTEM DISORDERS | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0723454-A1 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | Goldstein, Gideon (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995005841-A1 | NOVEL TRIPEPTIDES USEFUL IN IMMUNE AND CNS THERAPY | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1995-03-02 | — | — | WO | disclosed |